Cargando…

Exercise intolerance in pulmonary arterial hypertension: insight into central and peripheral pathophysiological mechanisms

Exercise intolerance is a cardinal symptom of pulmonary arterial hypertension (PAH) and strongly impacts patients' quality of life (QoL). Although central cardiopulmonary impairments limit peak oxygen consumption (V′(O(2peak))) in patients with PAH, several peripheral abnormalities have been de...

Descripción completa

Detalles Bibliográficos
Autores principales:	Malenfant, Simon, Lebret, Marius, Breton-Gagnon, Émilie, Potus, François, Paulin, Roxane, Bonnet, Sébastien, Provencher, Steeve
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Respiratory Society 2021
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9488698/ https://www.ncbi.nlm.nih.gov/pubmed/33853885 http://dx.doi.org/10.1183/16000617.0284-2020

Ejemplares similares

Signal transduction in the development of pulmonary arterial hypertension
por: Malenfant, Simon, et al.
Publicado: (2013)

Dual ET(A)/ET(B) blockade with macitentan improves both vascular remodeling and angiogenesis in pulmonary arterial hypertension
por: Nadeau, Valerie, et al.
Publicado: (2017)

COVID-19 and the pulmonary vasculature
por: Provencher, Steeve, et al.
Publicado: (2020)

DNA Damage and Pulmonary Hypertension
por: Ranchoux, Benoît, et al.
Publicado: (2016)

The cancer theory of pulmonary arterial hypertension
por: Boucherat, Olivier, et al.
Publicado: (2017)

Pim-1: A new biomarker in pulmonary arterial hypertension
por: Renard, Sébastien, et al.
Publicado: (2013)

Continuous reduction in cerebral oxygenation during endurance exercise in patients with pulmonary arterial hypertension
por: Malenfant, Simon, et al.
Publicado: (2020)

HDAC6: A Novel Histone Deacetylase Implicated in Pulmonary Arterial Hypertension
por: Boucherat, Olivier, et al.
Publicado: (2017)

Alternatives to the Six-Minute Walk Test in Pulmonary Arterial Hypertension
por: Mainguy, Vincent, et al.
Publicado: (2014)

PARP1-PKM2 Axis Mediates Right Ventricular Failure Associated With Pulmonary Arterial Hypertension
por: Shimauchi, Tsukasa, et al.
Publicado: (2022)

Neutrophil-Lymphocyte Ratio as an Independent Predictor of Survival in Pulmonary Arterial Hypertension: An Exploratory Study
por: Jutras-Beaudoin, Naomie, et al.
Publicado: (2021)

Assessment of Daily Life Physical Activities in Pulmonary Arterial Hypertension
por: Mainguy, Vincent, et al.
Publicado: (2011)

Involvement of PFKFB3 in Pulmonary Arterial Hypertension Pathogenesis. Is It All about Glycolysis?
por: Bonnet, Sebastien, et al.
Publicado: (2019)

Combination therapy in pulmonary arterial hypertension: recent accomplishments and future challenges
por: Lajoie, Annie-Christine, et al.
Publicado: (2017)

STAT3 signaling in pulmonary arterial hypertension
por: Paulin, Roxane, et al.
Publicado: (2012)

Krüppel-like Factor 5 contributes to pulmonary artery smooth muscle proliferation and resistance to apoptosis in human pulmonary arterial hypertension
por: Courboulin, Audrey, et al.
Publicado: (2011)

Compromised Cerebrovascular Regulation and Cerebral Oxygenation in Pulmonary Arterial Hypertension
por: Malenfant, Simon, et al.
Publicado: (2017)

Role for miR-204 in human pulmonary arterial hypertension
por: Courboulin, Audrey, et al.
Publicado: (2011)

Preclinical Investigation of Trifluoperazine as a Novel Therapeutic Agent for the Treatment of Pulmonary Arterial Hypertension
por: Grobs, Yann, et al.
Publicado: (2021)

Critical Role for the Advanced Glycation End‐Products Receptor in Pulmonary Arterial Hypertension Etiology
por: Meloche, Jolyane, et al.
Publicado: (2013)

Implication of EZH2 in the Pro-Proliferative and Apoptosis-Resistant Phenotype of Pulmonary Artery Smooth Muscle Cells in PAH: A Transcriptomic and Proteomic Approach
por: Habbout, Karima, et al.
Publicado: (2021)

Interpreting risk reduction in clinical trials for pulmonary arterial hypertension
por: Lajoie, Annie C., et al.
Publicado: (2018)

Pathophysiology and rehabilitation management of exercise intolerance in COVID-19 patients
por: Nazir, Arnengsih, et al.
Publicado: (2022)

Exercise Intolerance in Pulmonary Arterial Hypertension
por: Fowler, Robin M., et al.
Publicado: (2012)

Venous thromboembolism in COVID-19 compared to non-COVID-19 cohorts: A systematic review with meta-analysis
por: Mai, Vicky, et al.
Publicado: (2021)

Fetal Gene Reactivation in Pulmonary Arterial Hypertension: GOOD, BAD, or BOTH?
por: Lemay, Sarah-Eve, et al.
Publicado: (2021)

Contribution of Peripheral Chemoreceptors to Exercise Intolerance in Heart Failure
por: Kulej-Lyko, Katarzyna, et al.
Publicado: (2022)

Macrophage–NLRP3 Activation Promotes Right Ventricle Failure in Pulmonary Arterial Hypertension
por: Al-Qazazi, Ruaa, et al.
Publicado: (2022)

Responsiveness of Various Exercise-Testing Protocols to Therapeutic Interventions in COPD
por: Borel, Benoit, et al.
Publicado: (2013)

Pulmonary hypertension-targeted therapies in heart failure: A systematic review and meta-analysis
por: Guay, Charles-Antoine, et al.
Publicado: (2018)

2251: An estrogen receptor α (ERα)-BMPR2-apelin axis mediates 17β-estradiol’s protective effects on right ventricular function in experimental pulmonary hypertension (PH)
por: Lee Frump, Andrea, et al.
Publicado: (2018)

Sirtuin 3 and Uncouplin Protein 2, the Missing Link Between Genetics, Metabolism, and Pulmonary Arterial Hypertension
por: Lajoie, Annie C., et al.
Publicado: (2021)

Pathophysiology of exercise intolerance in chronic diseases: the role of diminished cardiac performance in mitochondrial and heart failure patients
por: McCoy, Jodi, et al.
Publicado: (2017)

Epigenetics, inflammation and metabolism in right heart failure associated with pulmonary hypertension
por: Samson, Nolwenn, et al.
Publicado: (2017)

The pathophysiology of glucose intolerance in newly diagnosed, untreated T2DM
por: Dunseath, Gareth J., et al.
Publicado: (2021)

Contribution of Colonic Fermentation and Fecal Water Toxicity to the Pathophysiology of Lactose-Intolerance
por: Windey, Karen, et al.
Publicado: (2015)

Reduced Systolic Volume: Main Pathophysiological Mechanism in Patients with Orthostatic Intolerance?
por: Távora-Mehta, Maria Zildany P., et al.
Publicado: (2016)

Quality of Life, Safety and Efficacy Profile of Thermostable Flolan in Pulmonary Arterial Hypertension
por: Provencher, Steeve, et al.
Publicado: (2015)

Identity crisis in pulmonary arterial hypertension
por: Ruffenach, G., et al.
Publicado: (2017)

Reply to Chen et al.: BET Signaling: A Novel Therapeutic Target for Pulmonary Hypertension?
por: Provencher, Steeve, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_i66pipklpdk1b0ti5ju06ct8a3